We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Time is on their side

13 September 2010 By Robert Cyran

The U.S. takeover target cleaned house a bit by unloading its genetictesting arm. The more Genzyme can do to fix itself up, the more likely it can squeeze the French Sanofi to sweeten its $18.5 bln bid. Biotechs, once in play, almost always sell. A higher bid seems likely.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)